At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
פוסטים אחרונים
- At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
- Sun Pharma and LIB Therapeutics announce global licensing agreement for Lerodalcibep
- Sun Pharma Launches CTaro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
תגובות אחרונות